Xspray Pharma publishes its Annual Report 2023

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/ An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma: “Throughout 2023, we continued to make significant progress on the exciting journey toward the […]

Read more

Interim Report Fourth Quarter 2023

October-December 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -54,513 thousand (-55,220) Earnings per share before dilution amounted to SEK -1.85 (-2.48) Cash flow from operating activities amounted to SEK -32,626 thousand (-35,003) Cash flow from investing activities amounted to SEK -20,729 thousand (-29,481) January-December 2023, Group […]

Read more

FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July

Stockholm, Sweden – Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc®, following a Complete Response Letter (CRL) where additional information was requested. The FDA has now assigned a Prescription Drug User Fee Act (PDUFA) date to […]

Read more

Xspray Pharma appoints Michael af Winklerfelt as acting CFO

Xspray Pharma has appointed Michael af Winklerfelt as acting CFO, beginning tomorrow, February 8th. The company’s current CFO Kerstin Hasselgren leaves the role at her own request and will transition to another internal role as Senior Advisor and Head of IR. Michael af Winklerfelt has extensive experience from similar roles at listed life science companies, […]

Read more

New number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the exercise of warrants series TO5 which were issued in connection with the rights issue in June this year, and for which the subscription period […]

Read more

Xspray Pharma raises SEK 92.3 million through warrants TO5

Xspray Pharma today compiled the outcome of exercised warrants of series TO5, issued in connection with the rights issue in June this year and for which the subscription period ended on November 30, 2023. In total, 2,307,242 series TO5-warrants were exercised to subscribe for new shares. Xspray Pharma thereby receives proceeds of SEK 92.3 million […]

Read more

Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage

Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage. XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase inhibitor (PKI) product candidate developed with Xspray’s HyNap™ technology TASIGNA is an import treatment for chronic myeloid leukemia (CML), […]

Read more

Important information to holders of warrants series TO5: The subscription period is ongoing

Holders of Xspray's warrants series TO5 can, during the period 16-30 November, subscribe for new shares in Xspray Pharma for a price of SEK 40. The warrants were issued in connection with the rights issue in June 2023. The proceeds from subscribed warrants will be used for the launch of Xspray's first product Dasynoc in […]

Read more

Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November

Xspray Pharma has received written declarations of intent whereby owners of 53 percent of shares in the company state their intent to exercise warrants TO5 to subscribe for newly issued shares corresponding to their holdings of warrants of series TO5 during the subscription period 16-30 November 2023 for the subscription price 40.00 SEK per share. […]

Read more

Interim Report Third Quarter 2023

July-September 2023, Group Net sales amounted to SEK 0 thousand (0)  Loss before tax amounted to SEK -38,942 thousand (-28,651) Earnings per share before dilution amounted to SEK -1.59 (-1.39) Cash flow from operating activities amounted to SEK -68,611 thousand (-23,091) Cash flow from investing activities amounted to SEK -14,470 thousand (-29,126) January-September 2023, Group  […]

Read more